[December 14, 2017] |
|
Stimwave Appoints Industry Veteran Jim Surek as Chief Commercialization Officer and Adds Konstantin Slavin, M.D. to Medical Advisory Board
Stimwave
LLC, a medical device manufacturer and independent research
institute headquartered in South Florida, announced the appointment of
Konstantin Slavin, M.D. to its medical board of advisors and the
appointment of industry veteran Jim Surek to the position of chief
commercialization officer. The expansion of the team is in direct
response to an ever-increasing demand for its Freedom Spinal Cord
Stimulation (SCS (News - Alert)) System and StimQ Peripheral Nerve Stimulator (PNS)
System for the treatment of chronic pain.
"Every day, increasing numbers of patients are seeking non-opioid
solutions to managing chronic pain, and it is essential that we do
everything we can to meet that demand and to serve those patients," said
Laura Tyler Perryman, co-founder and CEO of Stimwave. "The addition of
Dr. Slavin and Jim Surek strengthens our executive management team to
support our high growth and to meet these market needs."
Dr. Slavin currently serves as professor of neurosurgery at the
University of Illinois at Chicago and holds several leadership roles in
professional societies, including serving as president of the American
Society for Stereotactic and Functional Neurosurgery and as the director
at large for the International Neuromodulation Society. He is a
world-renowned expert in neuromodulation, most recently publishing his
second edition of "Peripheral Nerve Stimulation" and "Neurostimulation:
Principles and Practice."
"This miniature, wireless stimulator minimizes the need for surgery in
patients who are already suffering from pain, while allowing on-going
care and full-body MRI scan capabilities providing a viable, non-opioid
option for long-term pain management," said Dr. Slavin. "I am pleased to
join their prestigious board of experts in the field."
A 25-year idustry veteran, Jim Surek joins the Stimwave team as the
company's first chief commercialization officer. Surek received his
Master's in International Management from the Thunderbird School of
Global Management. Beginning his career as a spinal implant sales
representative at Medtronic in 1994, Surek rose through the ranks to
vice president of sales and development before taking on the role of the
first vice president of sales at Advanced Bionics in 2003, which
ultimately sold to Boston Scientific. He went on to become the vice
president of sales at Entellus Medical, Inc., which sold to Stryker
earlier this month.
"I'm thrilled to return to the field of neuromodulation with Stimwave.
It's an exciting time to be a part of a great neuromodulation team and
company setting the vision for the future for all pain patients across
the country," said Surek. "Stimwave's technology brings the future
forward through its miniaturization of the electronics and elimination
of a bulky, potentially dangerous implantable battery. Now,
physicians have a solution to treat a tremendously larger pain patient
population, since more than 80 percent of patients either cannot receive
treatment or refuse the surgery option to treat their pain."
Stimwave's devices use Wireless Pain Relief® technology and
are 95 percent smaller than any other neuromodulation device on the
market and can be anchored through an injectable method. The device
delivers small pulses of energy to specific nerves, triggering a
reaction that enables the brain to remap pain pathways, thus providing
pain relief. Stimwave launched its FDA-cleared devices for the relief of
chronic back and leg pain to a limited number of patients throughout
2015. In March 2016, Stimwave was granted FDA 510(k) for the relief of
peripheral nervous system (PNS) pain, becoming the only neuromodulation
device manufacturer cleared by the FDA to help reduce chronic
neuropathic pain at most locations throughout the body, from back and
leg pain addressed by spinal cord stimulation to PNS treatment for
shoulder pain, wrist and elbow pain, knee pain, hip pain and more.
About Stimwave
Stimwave Technologies Incorporated is a privately held medical device
company engaged in the development, manufacturing, and commercialization
of wirelessly powered, microtechnology neurostimulators, providing
patients with a convenient, safe, minimally invasive, and highly
cost-effective pain management solution that is easily incorporated into
their daily lives. Stimwave's goal is to evolve its patented,
cutting-edge platform into the default for neuromodulation, increasing
the accessibility for patients worldwide while lowering the economic
impact of pain management. www.stimwave.com
Statements made in this press release that look forward in time or
that express beliefs, expectations or hopes regarding future occurrences
or anticipated outcomes are forward-looking statements. A number of
risks and uncertainties such as risks associated with product
development and commercialization efforts, expected timing or results of
any clinical trials, ultimate clinical outcome and perceived or actual
advantages of the Company's products, market and physician acceptance of
the products, intellectual property protection, and competitive
offerings could cause actual events to adversely differ from the
expectations indicated in these forward looking statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171214005522/en/
[ Back To Mobile World Congress's Homepage ]
|